Celon Laboratories Ltd, a specialty biopharmaceutical company, is looking to expand in global markets , and plans to set up local entities in South and Central America, Africa, CIS countries and Asia-Pacific.

The Hyderabad-based company has already registered 114 products and launched them in 17 markets. Another 18 products are in the process of registration. The company has WHO-GMP approved facilities near Hyderabad.

“We are in the process of getting approval from several other regulatory bodies,” said Mr K.V. Ravindra, Founder of Celon Labs.

The confidence to go global stems from the good number of product registrations, pipeline and facilities being created, he said. The company also crossed Rs 100-crore turnover in 2010-11, according to a press release.

The company focuses on critical care in cancer, heart, gynaecology, anaesthesia and urology at present. It offers the largest product basket in the oncology segment with a good distribution network. To accelerate its growth, Celon Labs is setting up manufacturing facilities at Kolthur Village in Genome Valley spread over 11 acres, with an outlay of about Rs 120 crore.

Venture capital firm, Sequoia Capital, has invested Rs 70 crore in Celon Labs to support its growth plans.

Celon Labs has also received recognition for its in-house R&D facility from the Department of Scientific and Industrial Research (DSIR).

The R&D facility focuses on developing biotech products using microbial and cell culture-based technologies that complement the growth of critical care and gynaecology segments.

Related Topics
comment COMMENT NOW